Ionis Pharmaceuticals Inc
NASDAQ:IONS

Watchlist Manager
Ionis Pharmaceuticals Inc Logo
Ionis Pharmaceuticals Inc
NASDAQ:IONS
Watchlist
Price: 34.01 USD 0.21% Market Closed
Market Cap: 5.4B USD
Have any thoughts about
Ionis Pharmaceuticals Inc?
Write Note

Ionis Pharmaceuticals Inc
Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ionis Pharmaceuticals Inc
Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
Ionis Pharmaceuticals Inc
NASDAQ:IONS
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Minority Interest
$39m
CAGR 3-Years
13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ionis Pharmaceuticals Inc
Glance View

Market Cap
5.4B USD
Industry
Biotechnology

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 660 full-time employees. The firm is primarily focused on our cardiovascular and neurology franchises. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. The firm has over six medicines in Phase III studies for eight indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)) and Tofersen (SOD1). Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, ION449 (PCSK9), Fesomersen and IONIS-AGT-LRx.

IONS Intrinsic Value
40.4 USD
Undervaluation 16%
Intrinsic Value
Price

See Also

Back to Top